Amphista Therapeutics

OverviewSuggest Edit

Amphista Therapeutics is a biopharmaceutical company. It provides cancer therapeutics that harness the body's natural processes to degrade and remove disease-causing proteins.
TypePrivate
Founded2017
HQLondon, GB
Websiteamphista.com

Latest Updates

Employees (est.) (Jan 2022)27(+13%)
Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Amphista Therapeutics

Satish Jindal

Satish Jindal

Chairman
Raj Parekh

Raj Parekh

Non-Executive Director
Nicola Thompson

Nicola Thompson

CEO and Director
Ian Churcher

Ian Churcher

CSO
Rogier Rooswinkel

Rogier Rooswinkel

Non-Executive Director
Stefan Luzi

Stefan Luzi

Non-Executive Director
Show more

Amphista Therapeutics Office Locations

Amphista Therapeutics has offices in London and Motherwell
London, GB (HQ)
158 N Gower St, Kings Cross
Motherwell, GB
Bo'Ness Rd
Show all (2)

Amphista Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2017

Amphista Therapeutics total Funding

$60.5 m

Amphista Therapeutics latest funding size

$53 m

Time since last funding

10 months ago

Amphista Therapeutics investors

Amphista Therapeutics's latest funding round in March 2021 was reported to be $53 m. In total, Amphista Therapeutics has raised $60.5 m
Show all financial metrics

Amphista Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

79/100

SecurityScorecard logo

Amphista Therapeutics Online and Social Media Presence

Embed Graph

Amphista Therapeutics News and Updates

Amphista Therapeutics Appoints CBO, Beverley Carr

CAMBRIDGE, England, Nov. 1, 2021 /PRNewswire/ -- Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the appointment of a Chief Business Officer (CBO), Beverley Carr. Amphista's CEO Dr Nicola Thompson said, "On behalf of the...

Amphista Therapeutics Appoints New Chairman, Joshua T. Brumm

GLASGOW, Scotland, Sept. 21, 2021 /PRNewswire/ -- Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the appointment of Joshua T. Brumm as its new Independent Chairman, succeeding Satish Jindal. Amphista's CEO Dr Nicola...

Amphista Therapeutics Expands Research Team by Appointing Martin O'Rourke as Head of Drug Discovery and James Osborne as Director of Chemistry

GLASGOW, Scotland, June 28, 2021 /PRNewswire/ -- Amphista Therapeutics, a Targeted Protein Degradation (TPD) biopharmaceutical company creating first-in-class cancer therapeutics that harness the body's natural processes to remove disease-causing proteins selectively and efficiently,...

Amphista Therapeutics raises $53M in oversubscribed Series B round to advance next generation targeted protein degradation assets

GLASGOW, Scotland, March 17, 2021 /PRNewswire/ -- Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the closing of a $53 million (£38 million) Series B financing round. The round was co-led by Forbion and Gilde Healthcare....

Amphista Therapeutics Appoints Leading Protein Degradation Pioneer, Ian Churcher as CSO

GLASGOW, Scotland, May 21, 2020 /PRNewswire/ -- Amphista Therapeutics, a biopharmaceutical company creating first-in-class cancer therapeutics that harness the body's natural processes to remove disease causing proteins selectively and efficiently, today announced the appointment of Dr...

Amphista Therapeutics Raises $7.5M in Series A Funding

Amphista Therapeutics, a Glasgow, Scotland-based biopharmaceutical company, closed a USD $7.5m Series A funding round. The round was led by Advent Life Sciences with participation from the Scottish Investment Bank, the European Investment Fund, and BioMotiv. In conjunction with the funding, Satish J…

Amphista Therapeutics Frequently Asked Questions

  • When was Amphista Therapeutics founded?

    Amphista Therapeutics was founded in 2017.

  • Who are Amphista Therapeutics key executives?

    Amphista Therapeutics's key executives are Satish Jindal, Raj Parekh and Nicola Thompson.

  • How many employees does Amphista Therapeutics have?

    Amphista Therapeutics has 27 employees.

  • Who are Amphista Therapeutics competitors?

    Competitors of Amphista Therapeutics include Jiangsu Hansoh Pharmaceutical Group, Takeda Oncology and Biocon.

  • Where is Amphista Therapeutics headquarters?

    Amphista Therapeutics headquarters is located at 158 N Gower St, Kings Cross, London.

  • Where are Amphista Therapeutics offices?

    Amphista Therapeutics has offices in London and Motherwell.

  • How many offices does Amphista Therapeutics have?

    Amphista Therapeutics has 2 offices.